Seattle Genetics, Inc. Highlights ADCETRIS® (Brentuximab Vedotin) Phase 2 Clinical Data In Diffuse Large B-cell Lymphoma (DLBCL) At American Society of Hematology 2013

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced updated results from a phase 2 clinical trial of ADCETRIS (brentuximab vedotin) in diffuse large B-cell lymphoma (DLBCL) and other B-cell non-Hodgkin lymphomas. The data, which demonstrated an encouraging activity and tolerability profile in the relapsed and refractory setting, were presented in an oral presentation at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013.

Help employers find you! Check out all the jobs and post your resume.